Prostate cancer: LDR-EBRT tops HDR-EBRT

  • Slevin F & al.
  • Clin Transl Radiat Oncol
  • 1 Jan 2020

  • curated by Dawn O'Shea
  • Medical news
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

External beam radiotherapy (EBRT) in combination with low-dose rate brachytherapy (LDR-EBRT) may achieve more effective control of prostate cancer progression at 5  years compared with high-dose rate brachytherapy combined with EBRT (HDR-EBRT). That is the finding of a study carried out by Leeds Teaching Hospitals NHS Trust.

A multivariable analysis was performed using data from almost 300 men with intermediate- and high-risk prostate cancer treated with LDR-EBRT between 1996 and 2007 (n=116) and those treated with HDR-EBRT between 2007 and 2012 (n=171).

At 5 years, biochemical progression free survival (bPFS) was estimated to be 90.5% for the LDR-EBRT cohort and 77.6% for the HDR-EBRT cohort.

On multivariable analysis, patients treated with HDR-EBRT were more than twice as likely to experience biochemical progression compared with LDR-EBRT (HR 2.33; 95% CI 1.12-4.07).

Patients with Gleason ≥8 disease were over five times more likely to experience biochemical progression compared with Gleason 6 disease (HR 5.47; 95% CI 1.26-23.64).

Cumulative incidence of ≥grade 3 genitourinary for the LDR-EBRT and HDR-EBRT cohorts were 8% versus 4%. The incidence of gastrointestinal toxicities were 5% versus 1%, respectively. However, these differences did not reach statistical significance.

The authors concluded that LDR-EBRT may provide more effective PSA control at 5  years compared with HDR-EBRT. However, they said direct comparison of these treatments through randomised trials are recommended to investigate the hypothesis further.